WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announces that
response of colorectal cancer to treatment can be detected with their
innovative diagnostic agent (Tc-99m duramycin-TumorVue™) as early
as one day after a single administration of drug. Results from this
preclinical study were published online*.
“Although imaging agents such as 18F-FDG show great promise
as biomarkers for early response to targeted cancer therapy, conflicting
results are reported after immunotherapy. If our preclinical findings
can be confirmed in patients, TumorVue™ has the potential to fill
this gap since it does not seem to be hampered by the presence or
absence of an inflammatory response,” said Professor Sigrid Stroobants
of the Antwerp University Hospital (UZA).
“Detection of early treatment response will allow for improved
management of cancer patients in the clinic. This study demonstrated
that TumorVue™ enables readout of tumor response to targeted
therapy as early as one day after start of treatment,” said Dr. Leonie
Wyffels at the University of Antwerp’s Molecular Imaging Center Antwerp (UAntwerp-MICA).
“The superiority of TumorVue™ over 18F-FDG for early
detection of treatment response in colorectal tumors is exciting.”
Chris Pak, President and CEO of MTTI said, “We are encouraged by the
results of TumorVue™ for detection of treatment response to
targeted therapy as early as one day. Our goal is to translate these
findings into patients to differentiate responders from non-responders.
This innovative agent will be a powerful tool for personalized medicine
where cancer patients will be spared the toxicity of ineffective
UAntwerp-MICA was founded in 2010 as a joint effort by the UAntwerp
and the UZA and has become one of the front runners in
translational from bench to patient. UAntwerp is not an island:
we build bridges to secondary education, to industry and, by extension,
to society as a whole. With over 5,000 members of staff, UA is one of
the most important employers in Antwerp, Flanders’ largest city. More
MTTI is a privately held biotechnology company focused on the
development of diagnostic technologies. More information: www.mtarget.com.
*J Nucl Med. 2016 as doi:10.2967/jnumed.116.182014. 99mTc-duramycin
SPECT imaging of early tumor response to targeted therapy: a comparison
with 18F-FDG PET.